<DOC>
	<DOC>NCT00241462</DOC>
	<brief_summary>The purpose of this study is to identify which patients, receiving Faslodex within the approved label, benefit most from Faslodex treatment.</brief_summary>
	<brief_title>Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Postmenopausal Locally advanced or metastatic hormone sensitive breast cancer with known estrogen receptor (ER) and progesterone receptor (PR) status Patient had a recurrence during or after adjuvant antioestrogen treatment or progression of the disease during antioestrogen treatment Life threatening metastases</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>